anti-HER2-4AP ADC (Catalent Biologics)

N/A

Report date: 2025/01/26 19:00:42

Base Information

Drug Nameanti-HER2-4AP ADC (Catalent Biologics)

Drug Alias Nameanti-HER2 antibody-drug conjugates (Redwood Bioscience)CAT-01-106

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRedwood Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesCatalent Inc

Inactive CompaniesRedwood Bioscience Inc

Active IndicationsStomach NeoplasmsBreast Neoplasms

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A